<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893487</url>
  </required_header>
  <id_info>
    <org_study_id>18086</org_study_id>
    <secondary_id>NCI-2019-00144</secondary_id>
    <secondary_id>PNOC016</secondary_id>
    <nct_id>NCT03893487</nct_id>
  </id_info>
  <brief_title>Fimepinostat in Treating Brain Tumors in Children and Young Adults</brief_title>
  <acronym>PNOC016</acronym>
  <official_title>A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sabine Mueller, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Pediatric Neuro-Oncology Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cannonball Kids' Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Curis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well fimepinostat works in treating patients with newly diagnosed
      diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come
      back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed
      for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To confirm penetration of fimepinostat across the blood brain barrier (BBB) in children
      and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG), recurrent
      medulloblastoma, or recurrent high-grade glioma (HGG) by measuring concentration of
      fimepinostat and metabolite in primary tumor tissue.

      EXPLORATORY OBJECTIVES:

      I. To assess pharmacokinetics (PK) of fimepinostat in plasma and tumor tissue of children and
      young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.

      II. To assess pharmacodynamics (PD) of fimepinostat in children and young adults with newly
      diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG as measured by phosphorylation
      and acetylation in tumor tissue.

      III. To correlate acetylation and phosphorylation in tumor tissue with tissue and plasma PK
      levels.

      IV. To assess the safety and tolerability of fimepinostat in children and young adults with
      newly diagnosed DIPG, recurrent medulloblastoma, or recurrent HGG.

      V. To assess preliminary efficacy of fimepinostat given as monotherapy after surgery in
      children and young adults with newly diagnosed DIPG, recurrent medulloblastoma, or recurrent
      HGG, as based on progression-free survival (PFS) and objective response rate (ORR) as
      appropriate.

      OUTLINE:

      Patients receive fimepinostat orally (PO) once daily (QD) on days -2 to 0. Within 2 hours of
      receiving fimepinostat on day 0, patients undergo tumor resection.

      MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week.
      Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
      for up to 12 months from the time treatment begins. Should patients continue to derive
      clinical benefit, and not experience excess toxicity or progression, patients can continue to
      receive drug for up to 24 months or longer pending discussion with study chairs and study
      sponsor.

      After completion of study treatment, patients are followed up at 30 days, then every 3 months
      for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Penetration of fimepinostat across the blood brain barrier (BBB)</measure>
    <time_frame>During surgery or biopsy</time_frame>
    <description>Will be analyzed using descriptive statistics from results of fimepinostat concentrations measured within the tumor tissue collected at the time of a standard of care surgery or biopsy. Within each strata, Simon's two-stage design will be used.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Recurrent Anaplastic Astrocytoma</condition>
  <condition>Recurrent Glioblastoma</condition>
  <condition>Recurrent Malignant Glioma</condition>
  <condition>Recurrent Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (fimepinostat, tumor resection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fimepinostat by mouth once daily, on Days -2 to 0. Within 2 hours of receiving fimepinostat on Day 0, patients undergo tumor resection or biopsy as part of their standard of care.
MAINTENANCE PHASE: Patients receive fimepinostat by mouth, once daily for days 1-5 each week. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity for up to 12 months from the time treatment begins. Should patients continue to derive clinical benefit, and not experience excess toxicity or progression, patients can continue to receive drug for up to 24 months or longer pending discussion with study chairs and study sponsor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimepinostat</intervention_name>
    <description>Fimepinostat capsules</description>
    <arm_group_label>Treatment (fimepinostat, tumor resection)</arm_group_label>
    <other_name>CUDC-907</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (fimepinostat, tumor resection)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have one of the following histologically confirmed diagnoses (histologic
             confirmation from initial diagnosis acceptable, as appropriate):

               -  Stratum A: Newly diagnosed diffuse intrinsic pontine glioma (DIPG) (World Health
                  Organization [WHO] grade II-IV)- this stratum does not require tissue
                  confirmation at time of enrollment, but diagnostic confirmation will be required
                  to continue on study after biopsy. Patients with newly diagnosed DIPG will be
                  eligible to enroll before or after standard of care radiation, but must be
                  eligible for a biopsy and cannot have received any prior therapy other than
                  radiation. Patients enrolling after standard of care radiation must be enrolled
                  within 14 weeks of completion of radiotherapy

               -  Stratum B: Recurrent medulloblastoma (WHO grade IV), any molecular subtype

               -  Stratum C: Recurrent high-grade glioma (HGG), including anaplastic astrocytoma
                  (WHO grade III) and glioblastoma (WHO grade IV)

                    -  Stratum B &amp; C: Patients in the recurrent medulloblastoma or recurrent HGG
                       arm can have locally recurrent or disseminated disease, provided
                       resection/biopsy would still be clinically indicated. Disseminated disease
                       can be diagnosed by imaging or cerebrospinal fluid (CSF) cytology

          -  Patients must be able to swallow intact fimepinostat capsules or mini-tabs without
             chewing or crushing

          -  Patients must have body surface area (BSA) &gt;= 0.5 m^2

          -  Patients must undergo tumor tissue collection as part of their standard of care

               -  Minimum possible tissue collected must be equivalent to about 4-6 stereotactic
                  core biopsies

          -  Prior Therapy: Patients in the medulloblastoma and HGG strata will be allowed to have
             undergone prior therapy including surgery, chemotherapy, and radiation therapy.
             Patients in the DIPG stratum are not allowed to have prior therapy before the
             initiation of fimepinostat, with the exception of those patients who previously
             received radiation as per standard of care and have not yet undergone a biopsy. These
             patients will be eligible to enroll in the newly diagnosed DIPG stratum. Patients must
             have fully recovered from acute side effects related to previous anti-cancer
             therapies. Patients undergoing radiation during protocol therapy will not be permitted
             to receive other concomitant agents with radiation and pending initiation of
             maintenance with fimepinostat

               -  Myelosuppressive chemotherapy: At least 21 days after last dose of
                  myelosuppressive chemotherapy (42 days if prior nitrosourea)

               -  Hematopoietic growth factors: At least 14 days after last dose of a long-acting
                  growth factor or 7 days after short-acting growth factor or beyond time during
                  which adverse events are known to occur

               -  Biologic (anti-neoplastic agent): At least 7 days after last dose of a biologic
                  agent or beyond time during which adverse events are known to occur

               -  Monoclonal antibodies: At least 21 days after last dose of monoclonal antibody

               -  Radiotherapy:

                    -  At least 2 weeks after local palliative radiotherapy (XRT)

                    -  At least 3 months from craniospinal XRT, or XRT to &gt; 50% pelvis

               -  Surgery:

                    -  At least 21 days from major surgery (biopsy and central line
                       placement/removal are not considered major)

          -  Corticosteroids: Subjects who are receiving dexamethasone must be on a stable or
             decreasing dose for at least 7 days prior to enrollment

          -  Peripheral absolute neutrophil count (ANC) &gt;= 1000/mm^3

          -  Platelet count &gt;= 100,000/mm^3 (transfusion independent, defined as not receiving
             platelet transfusions for at least 7 days prior to enrollment)

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             milliliters (mL)/minute (min)/1.73 m^2 or

          -  A serum creatinine based on age/gender as follows:

               -  Age: Maximum Serum Creatinine (mg/dL)

               -  3 to &lt; 6 years: 0.8 (male), 0.8 (female)

               -  6 to &lt; 10 years: 1 (male), 1 (female)

               -  10 to &lt; 13 years: 1.2 (male), 1.2 (female)

               -  13 to &lt; 16 years: 1.5 (male), 1.4 (female)

               -  &gt;= 16 years: 1.7 (male), 1.4 (female)

          -  Bilirubin (sum of conjugated + unconjugated) =&lt; 1.5 x upper limit of normal (ULN) for
             age

          -  Serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =&lt; 110 U/L

          -  Serum albumin &gt;= 2 g/dL

          -  Neurologic function:

               -  Subjects with seizure disorder may be enrolled if well controlled

          -  Gastrointestinal function:

               -  Diarrhea &lt; grade 2 by Common Terminology Criteria for Adverse Events (CTCAE)
                  version (v)5.0

          -  Metabolic function:

               -  Non-fasting glucose &lt; 125 mg/dL without the use of antihyperglycemic agents

                    -  If non-fasting glucose &gt; 125 mg/dL, a fasting glucose should be done. If
                       fasting glucose =&lt; 160 mg/dL without the use of antihyperglycemic agents,
                       patient will meet adequate metabolic function criteria

          -  Cardiac function: corrected QT (QTc) &lt; 480 msec

          -  The effects of fimepinostat on the developing human fetus are unknown. For this
             reason, women of child-bearing potential and men must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry, for the duration of study participation and 30 days after completion of
             fimepinostat administration. Should a woman become pregnant or suspect she is pregnant
             while she or her partner is participating in this study, she should inform her
             treating physician immediately

          -  A legal parent/guardian or patient must be able to understand, and willing to sign, a
             written informed consent and assent document, as appropriate

        Exclusion Criteria:

          -  Subjects who have not recovered from acute adverse events due to therapeutic agents
             administered more than 4 weeks earlier

          -  Patients must not have received prior therapy with single-agent or combination histone
             deacetylase (HDAC) and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)
             inhibitors

          -  Subjects who are receiving any other investigational agent

          -  History of allergic reaction to compounds of similar chemical or biological
             composition to fimepinostat

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situation that would limit compliance with
             study requirements

          -  Patients with active human immunodeficiency virus (HIV) infection and with potential
             life-threatening consequences associated with immune-suppressive therapy

          -  Patients with history of type 1 or 2 diabetes mellitus

          -  Patients with gastrointestinal condition that could interfere with absorption or
             metabolism of fimepinostat
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Mueller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Medical Center-Mount Zion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roisheen Doherty</last_name>
    <phone>415-502-1600</phone>
    <email>PNOC_Regulatory@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Mueller, MD, PhD</last_name>
    <phone>877-827-3222</phone>
    <email>cancertrials@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Crawford, MD, MS</last_name>
      <phone>858-966-4939</phone>
      <email>jcrawford@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>John Crawford, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Hitchner</last_name>
      <phone>415-502-1600</phone>
      <email>PNOC_Regulatory@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Mueller, MD, PhD</last_name>
      <phone>877-827-3222</phone>
      <email>cancertrials@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Mueller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sridharan Gururangan, FRCP</last_name>
      <phone>352-294-8347</phone>
      <email>Sridharan.Gururangan@neurosurgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Sridharan Gururangan, FCRP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Cohen, MD, MBA</last_name>
      <phone>410-614-5055</phone>
      <email>kcohen@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Cohen, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan N Chi, MD</last_name>
      <phone>617-632-4386</phone>
      <email>Susan_Chi@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Susan N Chi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Rubin, MD, PhD</last_name>
      <phone>314-286-2790</phone>
      <email>rubin_j@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Rubin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University Children's Hospital in Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <state>Zurich</state>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gerber, MD</last_name>
      <phone>+41 44 266 31 17</phone>
    </contact>
    <contact_backup>
      <last_name>Stephanie Mathes, PhD</last_name>
      <phone>+41 44 266 3726</phone>
      <email>PNOC_regulatory@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sabine Mueller, MD, PhD</investigator_full_name>
    <investigator_title>Associate Adjunct Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

